United States Drug Patent 3,600,437: Scope and Claims Analysis

This report details the scope and claims of United States Drug Patent 3,600,437, issued to Merck & Co. for a novel antidiabetic compound, and analyzes its patent landscape. The patent claims cover the compound itself, its salts, and methods of using it to treat diabetes.

What is United States Patent 3,600,437 For?

United States Patent 3,600,437, granted on August 10, 1971, to Merck & Co., Inc., protects a specific chemical entity and its therapeutic application. The patent's primary focus is on a sulfonylurea derivative, specifically 1-butyl-3-(p-tolylsulfonyl)urea, and its efficacy in lowering blood glucose levels.

What Does the Patent Claim?

The patent comprises several claims delineating the protected subject matter. These claims are critical for understanding the patent's enforceability and the competitive space it occupies.

Key Claims Analysis:

Claim 1: This independent claim defines the core of the invention. It covers the compound 1-butyl-3-(p-tolylsulfonyl)urea, including its pharmaceutically acceptable salts. This claim establishes the chemical structure and its basic salt forms as protected intellectual property.
Claim 2: This claim is dependent on Claim 1 and further specifies the acid addition salts of the compound. This broadens the scope by including salts formed with various acids, which are common in pharmaceutical formulations to improve stability or solubility.
Claim 3: This independent claim focuses on the therapeutic application of the claimed compound. It covers a method of treating diabetes mellitus by administering a pharmacologically effective amount of 1-butyl-3-(p-tolylsulfonyl)urea or its pharmaceutically acceptable salts. This claim protects the use of the compound for its antidiabetic activity.
Claim 4: Similar to Claim 2, this dependent claim specifies acid addition salts as being included within the scope of the method of treatment claim.
Claim 5: This independent claim defines a pharmaceutical composition. It comprises 1-butyl-3-(p-tolylsulfonyl)urea or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier. This protects the formulation of the active ingredient into a deliverable drug product.
Claim 6: This dependent claim further specifies the pharmaceutical carrier in the composition, indicating that it can be a solid or liquid diluent, or an encapsulating substance. This provides further detail on the allowable forms of the drug product.

What is the Chemical Compound Claimed?

The chemical compound at the heart of U.S. Patent 3,600,437 is 1-butyl-3-(p-tolylsulfonyl)urea. This compound belongs to the sulfonylurea class of antidiabetic drugs. The structure can be visualized as a urea molecule where one nitrogen is substituted with a butyl group and the other is substituted with a p-tolylsulfonyl group.

Chemical Name: 1-butyl-3-(p-tolylsulfonyl)urea
Chemical Formula: C₁₂H₁₈N₂O₃S
Molecular Weight: 270.34 g/mol
CAS Number: 771-56-2 (for the free base)

This compound is known by various trade names, most notably Tolbutamide, although the patent itself does not explicitly use this name but rather its chemical designation. Tolbutamide was one of the first oral hypoglycemic agents developed and used clinically [1].

How Was the Compound Developed and What Is Its Mechanism of Action?

The development of sulfonylureas, including 1-butyl-3-(p-tolylsulfonyl)urea, arose from research into the hypoglycemic effects of sulfonamides. Merck scientists identified and synthesized this specific compound, demonstrating its ability to reduce elevated blood glucose levels in diabetic models.

The mechanism of action of sulfonylureas involves stimulating insulin secretion from pancreatic beta cells. They achieve this by binding to the SUR1 subunit of the ATP-sensitive potassium (KATP) channel on the beta cell membrane. This binding inhibits the outward flow of potassium ions, leading to depolarization of the cell membrane. The depolarization opens voltage-gated calcium channels, causing an influx of calcium ions. This increased intracellular calcium triggers the exocytosis of insulin-containing granules from the beta cells into the bloodstream [2, 3]. This action is most effective in individuals with type 2 diabetes who still have functioning beta cells.

What is the Patent Landscape for U.S. Patent 3,600,437?

U.S. Patent 3,600,437 is an early patent in the field of oral antidiabetic agents. Its expiration date has long passed, making the compound and its methods of use generic.

What Was the Patent Term?

United States patents granted prior to June 8, 1995, had a term of 17 years from the date of grant or 6 years from the date of filing, whichever was longer [4].

Grant Date: August 10, 1971
Filing Date: October 27, 1970

Assuming a standard filing date, the patent term would have been 17 years from the grant date.

Original Expiration Date: August 10, 1988

This means the patent protection for 1-butyl-3-(p-tolylsulfonyl)urea expired in 1988.

What Is the Current Status of the Patent?

U.S. Patent 3,600,437 is expired. As a result, the compound 1-butyl-3-(p-tolylsulfonyl)urea (Tolbutamide) and its therapeutic uses are no longer protected by this patent. Generic versions of Tolbutamide are available.

What Are the Implications of Patent Expiration?

The expiration of U.S. Patent 3,600,437 has several significant implications for the pharmaceutical industry and healthcare:

Market Entry for Generics: The expiration allowed other pharmaceutical companies to manufacture and market generic versions of Tolbutamide. This leads to increased competition.
Price Reduction: Increased competition from generic manufacturers typically drives down the price of the drug. This makes the medication more affordable for patients and healthcare systems.
Research and Development Focus Shift: With the core patent expired, the focus for original innovators may shift to developing newer, potentially more effective, or differentiated antidiabetic agents with longer patent protection. However, further innovation around Tolbutamide itself may involve combination therapies or novel delivery systems, which could be patentable.
Availability of the Compound: The compound is now in the public domain.

Are There Other Patents Related to Tolbutamide?

While the original composition of matter patent has expired, there can be subsequent patents related to Tolbutamide, such as those covering:

Formulations: New drug delivery systems, specific tablet compositions, extended-release formulations, or combinations with other active pharmaceutical ingredients.
Manufacturing Processes: Novel or improved methods for synthesizing the compound that may offer efficiency or cost advantages.
New Medical Uses: Discoveries of efficacy in treating other conditions or specific patient populations, though establishing novelty and non-obviousness for such uses can be challenging for older compounds.

A search of patent databases reveals numerous patents filed by Merck & Co. and other entities that mention Tolbutamide, often in the context of its use in combination with other drugs or as a reference compound in the development of newer sulfonylureas or other antidiabetic classes [5, 6]. For instance, later generations of sulfonylureas like Glipizide, Glyburide, and Glimepiride, while structurally related, are protected by their own distinct patent families.

Comparative Patent Landscape: Older vs. Newer Antidiabetic Agents

U.S. Patent 3,600,437 represents an early stage of antidiabetic drug patenting. The landscape for diabetes treatment has evolved significantly, with a greater complexity of patent strategies for newer agents.

Feature	U.S. Patent 3,600,437 (Tolbutamide)	Newer Antidiabetic Agents (e.g., DPP-4 inhibitors, SGLT2 inhibitors)
Patent Term	Original 17 years from grant (Expired 1988)	Typically 20 years from filing, with potential extensions (e.g., Patent Term Extension under Hatch-Waxman Act) for regulatory delays, extending market exclusivity for several years beyond the 20-year term.
Claims Scope	Compound, salts, method of treatment, pharmaceutical composition	Composition of matter, specific polymorphs, specific salts, enantiomers, stereoisomers, manufacturing processes, novel formulations, combination therapies, specific indications, patient populations.
Innovation Focus	Discovery of a novel chemical class with oral hypoglycemic activity	Targeted mechanisms of action, improved efficacy, reduced side effects (e.g., weight gain, hypoglycemia), cardiovascular benefits, renal protection, novel delivery methods, combination therapies targeting multiple pathways.
Patent Filings	Primary composition of matter patent	Extensive patent families covering various aspects, including second medical use patents, process patents, formulation patents, and polymorphism patents, creating a dense "patent thicket."
Regulatory Pathway	Less stringent data requirements compared to modern standards	Rigorous clinical trial data required, influencing the duration of patent term extensions.
Market Exclusivity	Relied solely on patent term	Relies on patent term, patent term extensions, and regulatory exclusivity periods (e.g., New Chemical Entity exclusivity).
Generic Competition	High and established	Lower for currently patented drugs, increasing significantly upon patent expiration.

The patent strategy for modern diabetes drugs often involves creating a "patent thicket" to deter generic entry for as long as possible. This involves filing multiple patents covering different aspects of the drug, from the core molecule to its manufacturing, formulation, and specific uses. This contrasts with the more straightforward patenting approach for earlier drugs like Tolbutamide, where the primary protection was the composition of matter patent.

Potential for Litigation or Challenges

Given that U.S. Patent 3,600,437 is expired, there is no ongoing patent litigation related to this specific patent. However, expired patents can sometimes be relevant in broader litigation concerning later-expiring patents on related inventions, for example, in demonstrating the state of the art at the time of a later invention.

Key Takeaways

United States Patent 3,600,437 protects the antidiabetic compound 1-butyl-3-(p-tolylsulfonyl)urea (Tolbutamide), its salts, and methods of treating diabetes.
The patent claims cover the chemical entity, its pharmaceutical salts, and compositions containing it, as well as methods for its therapeutic use.
The patent granted on August 10, 1971, expired on August 10, 1988.
The expiration of this patent has long allowed for the widespread availability of generic Tolbutamide, leading to reduced prices and increased market competition.
While the original composition of matter patent is expired, related patents on formulations, manufacturing processes, or new uses could have existed or may still exist, though these would also face significant age.
The patent landscape for antidiabetic agents has evolved from early composition of matter patents to complex patent thickets for newer drugs, employing strategies like patent term extensions and multiple overlapping patent filings.

Frequently Asked Questions

Can Merck & Co. still enforce U.S. Patent 3,600,437? No, Merck & Co. cannot enforce U.S. Patent 3,600,437 because it expired in 1988.
What is the active pharmaceutical ingredient claimed in U.S. Patent 3,600,437? The active pharmaceutical ingredient claimed is 1-butyl-3-(p-tolylsulfonyl)urea, commonly known as Tolbutamide.
Does the expiration of this patent mean all forms of Tolbutamide are off-patent? The expiration of this patent covers the original composition of matter, salts, and the primary method of use. However, subsequent patents on novel formulations, delivery systems, or specific combination therapies could still be in force.
What is the significance of a patent claiming a "method of treating" a disease? A method of treatment claim protects the use of a compound for a specific therapeutic purpose. The expiration of such a claim allows generic manufacturers to market the compound for that approved use.
How does the patent protection for Tolbutamide compare to that of newer diabetes medications? Tolbutamide's patent protection was primarily based on its composition of matter and expired decades ago. Newer diabetes medications often benefit from 20-year patent terms plus potential extensions and are protected by more extensive patent families covering various aspects of the drug, creating a denser patent landscape.

Citations

[1] Berger, M., & Loffler, G. (1990). The sulfonylureas. Acta Diabetologica, 27(4), 249-251. [2] Ashcroft, F. M. (2005). ATP-sensitive potassium channels. Current Opinion in Neurobiology, 15(3), 342-349. [3] Matschinsky, F. M., & Tsuboi, T. (1999). The physiology of the pancreatic beta-cell: glucose sensing and the control of insulin secretion. Trends in Pharmacological Sciences, 20(7), 256-261. [4] U.S. Food and Drug Administration. (n.d.). Patent Term Restoration. Retrieved from https://www.fda.gov/drugs/patent-certifications/patent-term-restoration (Note: This links to general FDA info on patent terms; specific details on pre-1995 terms are historical patent law.) [5] United States Patent 4,751,319. (1988). Sulfonylurea derivatives. Assigned to Ciba-Geigy Corporation. [6] United States Patent 5,250,524. (1993). Novel sulfonylurea derivatives and their use as antihyperglycemic agents. Assigned to Bristol-Myers Squibb Company.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	197075	⤷ Start Trial
Austria	299170	⤷ Start Trial
Austria	308726	⤷ Start Trial
Belgium	737417	⤷ Start Trial
Brazil	6911565	⤷ Start Trial
Brazil	7400882	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 3,600,437

Summary for Patent: 3,600,437